These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Azmoon S; Angiolillo DJ Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463 [TBL] [Abstract][Full Text] [Related]
4. A comprehensive comparative review of adenosine diphosphate receptor antagonists. Oh EY; Abraham T; Saad N; Rapp JH; Vastey FL; Balmir E Expert Opin Pharmacother; 2012 Feb; 13(2):175-91. PubMed ID: 22216937 [TBL] [Abstract][Full Text] [Related]
5. Ticagrelor for the treatment of arterial thrombosis. Gurbel PA; Kereiakes DJ; Tantry US Expert Opin Pharmacother; 2010 Sep; 11(13):2251-9. PubMed ID: 20707759 [TBL] [Abstract][Full Text] [Related]
6. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. White HD Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598 [TBL] [Abstract][Full Text] [Related]
7. The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Behan MW; Chew DP; Aylward PE Curr Opin Cardiol; 2010 Jul; 25(4):321-8. PubMed ID: 20386440 [TBL] [Abstract][Full Text] [Related]
8. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial. Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268 [TBL] [Abstract][Full Text] [Related]
11. Clopidogrel: the data, the experience, and the controversies. Sadanandan S; Singh IM Am J Cardiovasc Drugs; 2012 Dec; 12(6):361-74. PubMed ID: 23057989 [TBL] [Abstract][Full Text] [Related]
12. Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Gaglia MA; Waksman R Circulation; 2011 Feb; 123(4):451-6. PubMed ID: 21242480 [No Abstract] [Full Text] [Related]
13. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525 [TBL] [Abstract][Full Text] [Related]